Syschem Scales New Heights: ₹150-200 Million Boost for Amoxicillin Capacity Expansion

Syschem (India) Limited, a leading pharmaceutical manufacturer specializing in bulk drugs and antibiotics, has approved a strategic expansion plan involving an investment of ₹150-200 million. The company aims to significantly increase its amoxicillin production capacity by 1600 tonnes per annum (TPA) by setting up an additional WHO-GMP-compliant manufacturing unit in Haryana. This move underscores Syschem’s commitment to scaling operations and enhancing supply chain capabilities in the competitive pharmaceutical market.

 

Expansion Investment

Syschem India is investing between ₹150 million and ₹200 million to set up a new production unit in Haryana. This expansion will notably increase the company’s manufacturing footprint and operational scalability.

 

Capacity Increase

The expansion will boost the company's amoxicillin production capacity by 1600 TPA per annum, helping meet growing domestic and international demand for this key antibiotic.

 

New WHO-GMP-Compliant Unit

The facility under construction in Kalka, Haryana, will comply with WHO-GMP standards, ensuring high-quality production processes meeting global regulatory norms.

 

Business Growth and Market Presence

Syschem reported a 24% year-on-year revenue growth and a remarkable 1124% surge in profit before tax in recent quarters. Expanded production capacity aligns with its growth strategy across Indian and international markets including Africa, Latin America, and more.

 

Conclusion

The ₹150-200 million expansion and new facility development mark a significant step for Syschem (India) Ltd as it enhances amoxicillin production to capitalize on increasing health sector demand, reinforcing its position as a premium pharmaceutical manufacturer nationally and globally.

 

Sources: ScanX Trade, Market Screener, Moneycontrol, Trade Brains, Pharma Industry Reports